Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ensysce Biosciences (ENSCW) Shares Outstanding (Weighted Average) (2020 - 2025)

Historic Shares Outstanding (Weighted Average) for Ensysce Biosciences (ENSCW) over the last 6 years, with Q3 2025 value amounting to $2.9 million.

  • Ensysce Biosciences' Shares Outstanding (Weighted Average) rose 33770.54% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year increase of 33770.54%. This contributed to the annual value of $697686.0 for FY2024, which is 36223.66% up from last year.
  • As of Q3 2025, Ensysce Biosciences' Shares Outstanding (Weighted Average) stood at $2.9 million, which was up 33770.54% from $2.2 million recorded in Q2 2025.
  • In the past 5 years, Ensysce Biosciences' Shares Outstanding (Weighted Average) registered a high of $16.1 million during Q2 2021, and its lowest value of $113696.0 during Q1 2022.
  • For the 5-year period, Ensysce Biosciences' Shares Outstanding (Weighted Average) averaged around $2.6 million, with its median value being $1.0 million (2021).
  • In the last 5 years, Ensysce Biosciences' Shares Outstanding (Weighted Average) crashed by 9928.2% in 2022 and then surged by 182004.24% in 2023.
  • Over the past 5 years, Ensysce Biosciences' Shares Outstanding (Weighted Average) (Quarter) stood at $1.0 million in 2021, then plummeted by 82.15% to $179925.0 in 2022, then dropped by 16.11% to $150937.0 in 2023, then skyrocketed by 362.24% to $697686.0 in 2024, then skyrocketed by 313.66% to $2.9 million in 2025.
  • Its last three reported values are $2.9 million in Q3 2025, $2.2 million for Q2 2025, and $1.4 million during Q1 2025.